Gaudium IVF reports 17.9% Q2 revenue growth, margin pressure
Key highlights
- Gaudium IVF reported Q2 FY27 consolidated revenue of ₹37.41 crore, up 17.9% year on year.
- Q2 FY27 EBITDA was ₹13.47 crore and EBITDA margin declined to 36% from 43.4%.
- Q2 FY27 profit after tax was ₹9.41 crore, up 0.4% year on year.
- Gaudium IVF opened two new hubs, at South Extension in New Delhi and Gurgaon.
powered by IRIS

Gaudium IVF and Women Health Limited reported Q2 FY27 consolidated revenue of ₹37.41 crore, up 17.9% year on year, while EBITDA margin declined to 36% from 43.4% as it absorbed expansion costs. The company has also uploaded the audio recording of its November 16 earnings call covering the September-quarter and half-year results.
Know Gaudium IVF and Women Health inside out
Results, valuation, peers and who's buying, in one view.
What did Gaudium IVF report for Q2 FY27?
Gaudium IVF reported consolidated revenue of ₹37.41 crore for Q2 FY27, representing year-on-year growth of 17.9%. The company disclosed EBITDA of ₹13.47 crore, which was broadly flat, and profit after tax of ₹9.41 crore, up 0.4% year on year.
The key financial change was a reduction in profitability margins. EBITDA margin declined to 36% in Q2 FY27 from 43.4% a year earlier, a contraction of 740 basis points. Management attributed the pressure to the costs of ramping up new hubs and marketing expenditure.
Why did Gaudium IVF's margin decline?
Gaudium IVF said its margin contracted because it absorbed the initial costs of opening and scaling two new hubs. The facilities were opened at South Extension in New Delhi and Gurgaon during the period discussed on the earnings call.
Dr. Manika Khanna, Chairperson and Managing Director, said the existing hubs maintained their margins while the company bore the cost of bringing the new locations online. The available call material also identified marketing spending as a contributor to the lower consolidated margin.
This distinction matters because the reported margin pressure was linked to expansion activity rather than a stated deterioration in the performance of existing hubs. However, the company reported flat EBITDA despite higher revenue, showing that the additional revenue did not translate into comparable operating-profit growth in the quarter.
When was the Q2 FY27 earnings-call recording released?
Gaudium IVF uploaded the recording of its Q2 and H1 FY27 earnings call to its website after the call held on November 16, 2026. The call covered the company's unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.
The disclosure was made to BSE Limited and National Stock Exchange of India Limited under Regulation 30 and Regulation 46, read with Part A of Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Naveen Kumar, Company Secretary and Compliance Officer, signed the filing on November 16, 2026.
The recording is available at https://www.gaudiumivfcentre.com/audio-player/q2-and-h1-fy27. The call included Dr. Khanna, Chief Financial Officer Rakesh Sharma, Director Vishad Khanna, and investor-relations partner Adfactors PR.
Got a follow-up? Ask IRIS
How does the expansion affect investors and operations?
Gaudium IVF's Q2 numbers show revenue growth alongside a materially lower EBITDA margin. For investors, the result places attention on the relationship between the company’s hub expansion, associated operating costs, and the pace at which new facilities contribute to revenue and profitability.
The company indicated that demand conditions could be stronger in the second half, citing seasonality and medical-tourism demand. This was management commentary from the earnings call rather than a quantified earnings forecast. No specific revenue or margin target for the second half was provided in the supplied disclosure.
For patients and local operations, the two new hubs increase the company’s presence in South Extension and Gurgaon. The available material does not provide capacity, patient-volume, capital-expenditure, or break-even details for these locations.
What is the financial background for Gaudium IVF?
Gaudium IVF had reported consolidated revenue of ₹104.36 crore and profit after tax of ₹24.49 crore for FY26, according to a May 2026 earnings-call summary. That performance provides context for the company's current expansion efforts and its continued disclosures to the exchanges.
The Q2 FY27 update follows the company’s Q1 FY27 earnings call on August 14, 2026, which had a stated duration of 50 minutes. The Q2 call, also listed with a 50-minute duration, provides shareholders access to management commentary through the newly uploaded audio recording.
Conclusion
Gaudium IVF delivered 17.9% year-on-year consolidated revenue growth in Q2 FY27, but EBITDA margin fell 740 basis points to 36% as it funded the ramp-up of two new hubs and marketing activity. EBITDA remained flat and profit after tax increased only 0.4%, making profitability trends as relevant as revenue growth in assessing the quarter.
The next item to watch is management’s commentary on second-half seasonality and medical-tourism demand, alongside the operating progress of the South Extension and Gurgaon hubs. The company has made the November 16 call recording available, but the disclosed material does not specify financial targets or a timeline for the new hubs to mature.


